Status:
COMPLETED
Effectiveness of a Novel Exergame-Based Training Concept for Older Adults With Mild Neurocognitive Disorder
Lead Sponsor:
Eling DeBruin
Conditions:
Mild Neurocognitive Disorder
Eligibility:
All Genders
Phase:
NA
Brief Summary
BACKGROUND: Simultaneous motor-cognitive training interventions are considered promising to prevent the decline in cognitive functioning in older adults with mild neurocognitive disorder (mNCD) and c...
Detailed Description
BACKGROUND: Simultaneous motor-cognitive training interventions are considered promising to prevent the decline in cognitive functioning in older adults with mild neurocognitive disorder (mNCD) and c...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Participants fulfilling all of the following inclusion criteria are eligible for the study:
- (1 = mNCD) clinical diagnosis of 'Mild Neurocognitive Disorder' according to the International Classification of Diseases 11th Revision (ICD-XI) or the Diagnostic and statistical manual of mental disorders (DSM-5®)) OR (2 = sMCI) patients screened for mild cognitive impairment (sMCI) according to the following criteria: (a) informant (i.e. healthcare professionals)-based suspicion of MCI confirmed by (b) an objective screening of MCI based on the German Version of the Quick Mild Cognitive Impairment Screen with (b1) a recommended cut-off score for cognitive impairment (MCI or dementia) of \< 62/100 (doi: 10.3233/JAD-161204), while (b2) not falling below the cut-off score for dementia (i.e. \< 45/100 (doi: 10.3233/JAD-161204)).
- German speaking
- able to stand at least for 10 min without assistance
- EXCLUSION CRITERIA:
- The presence of any of the following exclusion criteria will lead to exclusion of the participants:
- mobility impairments (i.e. gait, balance) that prevent experiment participation
- presence of additional, clinically relevant (i.e. acute and/or symptomatic) neurological disorders (i.e. epilepsy, stroke, multiple sclerosis, Parkinson's disease, brain tumors, or traumatic disorders of the nervous system)
- presence of any other unstable or uncontrolled diseases
- Additional exclusion criteria will comprise of Covid-19 specific exclusion criteria (according to the Federal Office of Public Health). In case of Covid-19 specific exclusion criteria, participation in the study will only be allowed in case the treating physician provided written informed consent to allow participation in this study despite the presence of Covid-19 specific exclusion criteria. These Covid-19 specific exclusion criteria will include:
- high blood pressure (self-reported; systolic ≥ 140 mmHg and/or Diastolic ≥ 90 mmHg)
- Chronic respiratory condition
- uncontrolled type 2 Diabetes
- Condition or therapy that weakens the immune system
- unstable Cardiovascular Disease
- Cancer (present and/or under treatment)
- Serious obesity (BMI ≥ 40 kg/m2)
Exclusion
Key Trial Info
Start Date :
June 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2024
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT05387057
Start Date
June 22 2022
End Date
February 14 2024
Last Update
June 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ETH Zurich
Zurich, Switzerland, 8093